MO Stock Analysis: Altria | NYSE
Tobacco | NYSE, USA | Market Cap: 117.049m USD | 12M Return: 14.7% | US02209S1033 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 547M
EPS Trend: 96.6%
Qual. Beats: 0
Rev. Trend: 40.7%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Altria Group is a major U.S. tobacco company headquartered in Richmond, Virginia, founded in 1822. The company manufactures and sells a portfolio of smokeable and oral tobacco products, with its flagship Marlboro cigarette brand dominating the U.S. cigarette market. Beyond cigarettes, Altria offers large cigars and pipe tobacco (Black & Mild), moist smokeless tobacco and traditional oral products (Copenhagen, Skoal, Red Seal, Husky), oral nicotine pouches (on!), and e-vapor products (NJOY ACE). Its products are distributed through wholesale distributors and large retail chains.
As a Consumer Staples company in the GICS Tobacco sub-industry, Altria operates in a heavily regulated sector with strict marketing restrictions and ongoing litigation exposure. The tobacco industry has long faced secular volume declines in traditional cigarettes, prompting major producers to invest in reduced-risk products such as nicotine pouches and e-vapor as potential growth areas, though these categories remain smaller than legacy tobacco lines.
- Marlboro cigarette volumes decline as smoking rates fall
- On! oral nicotine pouches gain share against Zyn
- FDA moves toward menthol cigarette ban and oral pouch approval
| Net Income: 7.97b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.25 > 0.02 and ΔFCF/TA -2.12 > 1.0 |
| NWC/Revenue: -19.86% < 20% (prev -20.51%; Δ 0.66% < -1%) |
| CFO/TA 0.26 > 3% & CFO 8.64b > Net Income 7.97b |
| Net Debt (22.2b) to EBITDA (12.5b): 1.78 < 3 |
| Current Ratio: 0.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.67b) vs 12m ago -0.71% < -2% |
| Gross Margin: 70.99% > 18% (prev 71.63%; Δ -0.64% > 0.5%) |
| Asset Turnover: 66.57% > 50% (prev 62.66%; Δ 3.91% > 0%) |
| Interest Coverage Ratio: 10.26 > 6 (EBIT TTM 12.2b / Interest Expense TTM 1.19b) |
| A: -0.13 (Total Current Assets 3.43b - Total Current Liabilities 7.77b) / Total Assets 33.4b |
| B: 1.09 (Retained Earnings 36.4b / Total Assets 33.4b) |
| C: 0.37 (EBIT TTM 12.2b / Avg Total Assets 32.9b) |
| D: -0.07 (Book Value of Equity -2.67b / Total Liabilities 36.0b) |
| Altman-Z'' = 5.12 = AAA |
| DSRI: 1.18 (Receivables 306.0m/241.0m, Revenue 21.9b/20.3b) |
| GMI: 1.01 (GM 71.63% / 70.99%) |
| AQI: 0.97 (AQ_t 0.84 / AQ_t-1 0.87) |
| SGI: 1.08 (Revenue 21.9b / 20.3b) |
| TATA: -0.02 (NI 7.97b - CFO 8.64b) / TA 33.4b) |
| Beneish M = -2.83 (Cap -4..+1) = A |
As of September 22, 2026, the stock is trading at USD 68.53 with a total of 7,383,275 shares traded. Over the past week, the price has changed by -1.40%, over one month by +5.35%, over three months by +0.16% and over the past year by +14.70%.
Current recommended Stop Loss: 66.60 (which is 2.8% or 1.3 ATR below the current price).
Altria has received a consensus analysts rating of 3.38. Therefore, it is recommended to hold MO.
- StrongBuy: 4
- Buy: 0
- Hold: 7
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 70 | 2.1% |
P/E Trailing = 14.696
P/E Forward = 12.0337
P/S = 5.7253
P/B = 25.2407
P/EG = 2.6747
Revenue TTM = 21.9b USD
EBIT TTM = 12.2b USD
EBITDA TTM = 12.5b USD
Long Term Debt = 22.9b USD (from longTermDebt, last quarter)
Short Term Debt = 1.68b USD (from shortTermDebt, last quarter)
Debt = 24.6b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 22.2b USD (calculated: Debt 24.6b - CCE 2.37b)
Enterprise Value = 139b USD (117b + Debt 24.6b - CCE 2.37b)
Interest Coverage Ratio = 10.26 (Ebit TTM 12.2b / Interest Expense TTM 1.19b)
EV/FCF = 16.77x (Enterprise Value 139b / FCF TTM 8.30b)
FCF Yield = 5.96% (FCF TTM 8.30b / Enterprise Value 139b)
FCF Margin = 37.97% (FCF TTM 8.30b / Revenue TTM 21.9b)
Net Margin = 36.46% (Net Income TTM 7.97b / Revenue TTM 21.9b)
Gross Margin = 70.99% ((Revenue TTM 21.9b - Cost of Revenue TTM 6.34b) / Revenue TTM)
Gross Margin QoQ = 74.86% (prev 64.59%)
Tobins Q-Ratio = 4.17 (Enterprise Value 139b / Total Assets 33.4b)
Interest Expense / Debt = 4.85% (Interest Expense 1.19b / Debt 24.6b)
Taxrate = 23.16% (2.40b / 10.4b)
NOPAT = 9.40b (EBIT 12.2b * (1 - 23.16%))
Current Ratio = 0.44 (Total Current Assets 3.43b / Total Current Liabilities 7.77b)
Debt / Equity = -9.21 (negative equity) (Debt 24.6b / totalStockholderEquity, last quarter -2.67b)
Debt / EBITDA = 1.78 (Net Debt 22.2b / EBITDA 12.5b)
Debt / FCF = 2.67 (Net Debt 22.2b / FCF TTM 8.30b)
Total Stockholder Equity = -3.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 24.27% (Net Income 7.97b / Total Assets 33.4b)
RoE = -265.2% (negative equity) (Net Income TTM 7.97b / Total Stockholder Equity -3.01b)
RoCE = 61.52% (EBIT 12.2b / Capital Employed (Equity -3.01b + L.T.Debt 22.9b))
RoIC = 35.89% (NOPAT 9.40b / Invested Capital 26.2b)
WACC = 4.33% (E(117b)/V(142b) * Re(4.45%) + D(24.6b)/V(142b) * Rd(4.85%) * (1-Tc(0.23)))
Discount Rate = 4.45% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -87.98 | Cagr: -2.20%
[DCF] Terminal Value 74.76% ; FCFF base≈8.47b ; Y1≈8.16b ; Y5≈7.96b
[DCF] Fair Price = 61.48 (EV 125b - Net Debt 22.2b = Equity 103b / Shares 1.67b; r=8.35% [WACC [floored]]; 5y FCF grow -4.87% → 2.50% )
EPS Correlation: 96.63 | EPS CAGR: 5.13% | SUE: -0.55 | # QB: 0
Revenue Correlation: 40.74 | Revenue CAGR: 1.05% | SUE: 2.44 | # QB: 2
EPS current Quarter (2026-09-30): EPS=1.51 | Chg30d=-0.03% | Revisions=+25% | Analysts=11
EPS current Year (2026-12-31): EPS=5.68 | Chg30d=-0.15% | Revisions=-25% | GrowthEPS=+4.7% | GrowthRev=+2.2%
EPS next Year (2027-12-31): EPS=5.86 | Chg30d=-0.20% | Revisions=-25% | GrowthEPS=+3.3% | GrowthRev=+0.9%
[Analyst] Revisions Ratio: -10% (up=12, down=15)